Daphne Koller

Cutting-edge genome editing and machine learning help her develop drug therapies.

Company name:
Insitro
Location:
South San FranciscoCA 
Founded:
2018
Industry:
Science Pioneers
Daphne Koller. Photo Credit: Courtesy subject

Bay Area-based Insitro is combining several cutting-edge areas of science to develop new drug therapies. Daphne Koller--Stanford’s first-ever professor of machine learning and formerly co-CEO of Coursera--founded the company in spring 2018 and soon secured $100 million in funding from investors including Andreessen Horowitz, Jeff Bezos, and GV. Insitro uses Crispr genome editing to create unhealthy human cells in test tubes, and then applies hundreds of different interventions on the cells and tracks their effects. Based on the data collected, along with publicly available data sets, the startup develops treatments using machine learning. In April, Insitro announced a partnership with pharma giant Gilead Sciences to aid in the development of new therapies for nonalcoholic steatohepatitis, a liver disease that affects 16 million Americans. Insitro received $15 million up front and will earn royalties on any drug that its technology helps develop. --Kevin J. Ryan

MORE COMPANY INFORMATION

Twitter:
@insitro
Website:
insitro.com